Clinicopathological characteristics and prognostic analysis of multifocal/multicentric breast cancer Authors: Jiaxin Zhang, Hong Fang, Ziwei Zhao, Yaqiu Guo, Ying Li, Ya Wang, Xin Guo, Zhen Ning, Hongjiang Wang Published: 2025 ABSTRACT AbstractTo explore the correlation between the clinicopathological characteristics and prognosis of multifocal/multicentric breast cancer (MMBC), the clinicopathological data of 262 patients with multifocal/multicentric breast cancer and 1,745 patients with unifocal breast cancer (UFBC) were retrospectively collected and followed up. The analysis of the differences in clinicopathological characteristics showed that compared with patients with UFBC, patients with MMBC had a higher proportion of those aged ≤ 40 years (P < 0.001), premenopausal status (P < 0.001), “other types of invasive carcinoma” in histological types (P < 0.001), negative HER2 expression (P = 0.010), and absence of nerve invasion (P < 0.001), a lower proportion of those with a lower histological grade (P < 0.001), receiving chemotherapy after surgery (P = 0.018), and receiving targeted therapy after surgery (P = 0.023). The results of Survival analysis showed that there was no statistically significant difference in disease-free Survival (DFS) between the two groups of people (P = 0.199), while the difference in Overall Survival (OS) was statistically significant (P = 0.003). This may be related to the higher lymph node metastasis rate and tumor burden in MMBC patients. The clinicopathological characteristics and prognosis analysis of MMBC showed that menopause and clinical stage III were independent risk factors affecting DFS (P < 0.05), and menopause was an independent risk factor affecting OS (P = 0.010). In conclusion, this study confirmed that MMBC has different clinicopathological features from UFBC, which may be related to the prognostic differences between the two. Additionally, for MMBC patients who have reached menopause and have a higher clinical stage, more comprehensive assessment and individualized treatment are required.Keywords: Multifocal/multicentric breast cancer, Clinicopathological characteristics, PrognosisSubject terms: Breast cancer, Medical research, Oncology, Risk factors Introduction Breast cancer is one of the most common malignant tumors in women and also one of the main causes of cancer-related deaths in women1–3. Although the overall prognosis of breast cancer has significantly improved with the development of early screening, precision medicine and comprehensive treatment strategies, its heterogeneous pathological features and clinical manifestations still pose huge challenges to diagnosis and treatment decisions4. Based on imaging (mammography, ultrasound or Magnetic Resonance Imaging) and postoperative pathological reports, Multifocal Breast Cancer (MFBC) is defined as the presence of two or more isolated Cancer foci in the same quadrant. Multicentric Breast Cancer (MCBC) is defined as the presence of two or more isolated cancer foci in different quadrants, with a distance between the two foci greater than 5 cm. Due to their special pathological morphology and biological characteristics, both have become hotspots in Breast Cancer research in recent years. These two types of breast cancer are classified as MMBC, and MMBC is also analyzed in this study. In recent years, with the popularization of high-resolution imaging technologies (such as MRI), the detection rate of MMBC has significantly increased. According to literature reports, its incidence rate accounts for approximately 4% to 60% of all breast cancer patients5–8, suggesting that the actual incidence rate may be higher than that in earlier studies. One of the notable features of MMBC is tumor heterogeneity, which can be manifested at multiple levels such as histological type, pathological grade and molecular typing. It can exist between different lesions or show differences within the same lesion9,10. Boros, Burrell et al. ‘s research indicates that the molecular typing differences among different lesions of MMBC may affect the formulation of adjuvant treatment regimens, which will further impact the survival of breast cancer patients11,12. Buggi et al. ‘s research shows that among 113 MMBC patients, 14 cases (12.4%) received molecular typing analysis for smaller tumor lesions, and additionally received HER2-targeted therapy and the application of immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors), which significantly improved the prognosis13. Of course, there are also studies that have confirmed that in MMBC patients, heterogeneity has no significant impact on recurrence and survival14. These findings are worthy of further exploration of the necessity of immunohistochemistry for all tumor lesions found in breast cancer specimens, regardless of whether different lesions have the same histological type and grade. This will ensure that patients with multifocal breast cancer are recommended for appropriate individualized treatment. Due to the wide distribution of MMBC lesions, it is traditionally believed that breast-conserving surgery poses technical challenges, and surgical treatment often requires more extensive resection or mastectomy8. At present, MRI of the breast has been proven to be more accurate than traditional imaging in detecting MMBC. Studies have shown that through precise preoperative MRI assessment combined with intraoperative margin monitoring, some patients can achieve breast-conserving treatment. The local recurrence rate was not significantly different from that of UFBC15–17; However, studies by Chung A P et al. suggest that the risk of local recurrence (LR) after breast-conserving surgery for MMBC significantly increases18. In 2017, the ST. Gallen International Expert Consensus held that for MF and MC breast cancer, if the surgical margin is negative and radiotherapy is expected, breast preservation is recommended19. In breast-conserving surgery for MMBC patients, achieving a negative resection margin is technically demanding. Therefore, accurate tumor localization and precise resection are of crucial importance20,21, and in the future, the sample size needs to be expanded to verify its safety. The clinical manifestations of MMBC are more complex, and its biological behavior and prognosis have long been controversial. Existing studies present contradictory conclusions: research indicates that MMBC has higher invasiveness and poorer prognosis, including lower survival rates, higher recurrence rates, and higher lymph node metastasis rates2,5,7,22. However, research by scholars such as Ozturk reported that the OS and DFS of MMBC patients were similar to those of UFBC patients6; Other studies have shown that after adjusting for confounding factors such as tumor stage, the prognostic differences between MMBC and UFBC tend to disappear, and these academic controversies persist22. Therefore, an in-depth analysis of the clinicopathological features and biological behaviors of MMBC, as well as the establishment of individualized treatment, is an urgent need nowadays. This study aims to explore the independent risk factors of MMBC and their impact on prognosis, providing theoretical basis and ideas for optimizing individualized and precise treatment of MMBC patients. Materials and methods Research subjects and data The clinicopathological data of patients diagnosed with breast cancer in the Breast Surgery Department of the First Affiliated Hospital of Dalian Medical University and Zhongshan Hospital Affiliated to Dalian University from September 1, 2010 to December 31, 2022 were retrospectively collected. All were based on the pathological diagnosis reports of radical specimens after surgical resection to ensure the comprehensiveness and accuracy of the assessment. A total of 2007 enrolled patients were screened out according to the inclusion and exclusion criteria (Fig. 1), and they were followed up to obtain information such as the recurrence and survival status and time of breast cancer in the patients. Study ow chart: Flow diagram of patient selection steps. Biomarkers and molecular typing criteria: ER and PR positivity are defined as ≥ 1% tumor nuclear staining. HER2 positivity is defined as IHC 3 + or IHC 2 + with FISH amplification. The Ki-67 proliferation index was stratified with 14% as the boundary. Molecular typing is defined as: Luminal A type (ER + and/or PR+, HER2-, Ki-67 ≤ 14%), Luminal B type (ER + and/or PR+, HER2-, Ki-67 > 14%; Or ER + and/or PR+, HER2+), HER2-positive type (ER-, PR-, HER2+) and triple-negative type (ER-, PR-, HER2-)23. Targeted therapy: In this study, targeted therapy refers to the treatment approach of applying targeted drugs (trastuzumab, pertuzumab) to the HER2 receptor of cancer cells. Screening criteria Inclusion Criteria: (1) Aged between 18 and 80 years old. (2) Patients with newly diagnosed breast cancer who received unilateral radical mastectomy (including modified radical mastectomy for breast cancer, standard radical mastectomy for breast cancer, radical mastectomy with breast conservation, and mastectomy and reconstruction with preservation of the nipple-areola complex). (3) Received standard adjuvant treatment after surgery. (4) Complete clinical information, pathological information, and follow-up data. Exclusion Criteria: (1) Patients with a history of previously diagnosed primary malignant tumors and those who have received radiotherapy and chemotherapy (including neoadjuvant treatment for breast cancer). (2) Certain special types of breast cancer, such as inflammatory breast cancer, cutaneous breast cancer, and ductal carcinoma in situ of the breast. (3) Bilateral breast cancer. (4) Stage IV breast cancer. (5) Patients who did not receive standard radical surgical treatment. (6) Missing clinicopathological data and follow-up data. (7) Exclude patients with severe comorbidities (such as advanced heart disease, liver and kidney failure, diabetes, etc.) because these diseases may affect the choice of treatment regimen and the patient’s tolerance, thus interfering with the research results. (8) Male breast cancer patients. Research endpoints The primary endpoint of this study was OS, which was the time from radical surgery to death or the termination of follow-up. The secondary endpoint was DFS, which was the time from radical surgery to recurrence, metastasis of breast cancer or death from any cause. Statistical analysis Software such as IBM SPSS Statistics 27.0 (https://www.ibm.com/analytics/spss-statistics-software) was adopted. Categorical variables are expressed in terms of proportion and frequency. The comparison of counting data rates was conducted using the Pearson chi-square test. If the theoretical frequency (expected frequency) was less than 5 or the sample size was small, the Fisher’s exact test was used. The Log-rank test was used for univariate analysis, and the bidirectional stepwise regression Cox proportional hazards model was used for multivariate analysis, showing only the factors that had a significant impact on prognosis. The Kaplan-Meier method was used to evaluate the DFS and OS of the patients. Calculate the hazard ratio (HR) and confidence interval (CI). For all the above analyses, a P value < 0.05 was considered statistically significant. The observation period for survival analyses commenced one year postoperatively and concluded at the occurrence of the endpoint event (DFS: recurrence, metastasis, or death; OS: all-cause death) or the last follow-up visit.” Ethical review This study is a multicenter retrospective study and has been approved by the ethics committees of the First Affiliated Hospital of Dalian Medical University and Zhongshan Hospital Affiliated to Dalian University. The study will be conducted in accordance with the Declaration of Helsinki and the Measures for Ethical Review of Biomedical Research Involving Human Subjects and other relevant Chinese clinical research norms and regulations. According to the type of study conducted, the need for the informed consent form of patients is waived. Results Clinical characteristics This study compared and analyzed the clinicopathological characteristics of patients with MMBC(n = 262) and UFBC(n = 1745). The results of the chi-square test showed that MMBC patients were younger (the proportion of those ≤ 40 years old was 20.6% vs. 8.8%, P < 0.001) and had a higher proportion of premenopausal status (54.2% vs. 38.3%, P < 0.001). In terms of pathological characteristics, the proportion of invasive ductal carcinoma in MMBC (74% vs. 93%, P < 0.001) and the nerve invasion rate (2.7% vs. 10.4%, P < 0.001) were significantly lower than those in the UFBC group. The proportion of “other types of invasive carcinoma” (20.6% vs. 4.2%, P < 0.001) and histological grade II (73.3% vs. 54.3%, P < 0.001) was higher. In immunohistochemistry, the positive expression rate of HER2 in the MMBC group was lower than that in the UFBC group (20.6% vs. 28.2%, P = 0.010), while there was no significant difference in the positive expression rates of ER/PR and Ki-67 (P > 0.05). In terms of treatment, the proportions of patients receiving chemotherapy (85.5% vs. 90.3%, P = 0.018) and targeted therapy (21% vs. 27.7%, P = 0.023) in the MMBC group were lower. However, there was no statistical difference in the surgical method (breast conservation/total mastectomy) and the choice of radiotherapy between the MMBC group and the UFBC group (P > 0.05). There was no statistical difference in the remaining characteristics, as shown in Table 1. Table 1Clinicopathological characteristics of patients with UFBC and MMBC.CharacteristicsUFBC, n(%)MMBC, n(%)P valuen1745262Age < 0.001 > 401591(91.2%)208(79.4%) ≤ 40154(8.8%)54(20.6%)Menstrual status < 0.001 Postmenopausal1077(61.7%)120(45.8%) Premenopausal668(38.3%)142(54.2%)Surgical method0.616 Breast-conserving surgery212(12.1%)29(11.1%) Mastectomy1533(87.9%)233(88.9%)Histological type < 0.001 Invasive ductal carcinoma1623(93.0%)194(74.0%) Invasive lobular carcinoma49(2.8%)14(5.3%) Other invasive carcinomas73(4.2%)54(20.6%)Histological grade < 0.001 Ⅰ38(2.2%)8(3.1%) Ⅱ948(54.3%)192(73.3%) Ⅲ759(43.5%)62(23.7%)T staging0.931 T11004(57.5%)150(57.3%) T2 ~ T4741(42.5%)112(42.7%)N staging0.981 N01071(61.4%)161(61.5%) N1 ~ N3465(26.6%)73(27.9%)Clinical staging0.560 Ⅰ709(40.6%)109(41.6%) Ⅱ808(46.3%)125(47.7%) Ⅲ228(13.1%)28(10.7%)ER0.148 Positive1294(74.2%)209(79.8%) Negative383(21.9%)45(17.2%) Weakly positive68(3.9%)8(3.1%)PR0.503 Positive1094(62.7%)171(65.3%) Negative479(27.4%)63(24%) Weakly positive172(9.9%)28(10.7%)HER2 0.010 Positive492(28.2%)54(20.6%) Negative1253(71.8%)208(79.4%)Ki-670.200 >14%1348 (77.2%)193 (73.7%) ≤ 14%397 (22.8%)69 (26.3%)Molecular subtype0.261 Luminal A313 (17.9%)57 (21.8%) Luminal B1071 (61.4%)160 (61.1%) Her2(+)188 (10.8%)20 (7.6%) Triple173 (9.9%)25 (9.5%)Vascular tumor embolus0.534 Yes312 (17.9%)51 (19.5%) No1433 (82.1%)211 (80.5%)Neural invasion < 0.001 Yes181 (10.4%)7 (2.7%) No1564 (89.6%)255 (97.3%)Soft tissue invasion0.070 Yes45 (2.6%)2 (0.8%) No1700 (97.4%)260 (99.2%)Chemotherapy 0.018 Yes1575 (90.3%)224 (85.5%) No170 (9.7%)38 (14.5%)Radiotherapy0.937 Yes808 (46.3%)122 (46.6%) No937 (53.7%)140 (53.4%)Endocrine therapy0.364 Yes1376 (78.9%)213 (81.3%) No369 (21.1%)49 (18.7%)Targeted therapy 0.023 Yes483 (27.7%)55 (21.0%) No1262 (72.3%)207(79.0%) Clinicopathological characteristics of patients with UFBC and MMBC. Survival analysis Prognostic differences between MMBC and UFBC patients The Kaplan-Meier survival analysis showed that there was no statistical difference in DFS between the two groups (P = 0.199), while there was a significant difference in OS (P = 0.003) (Fig. 2). In the survival analysis of different molecular subtypes, there was a significant difference in OS between MMBC patients and UFBC patients with luminal B subtype (P = 0.004), and there was no statistical difference in DFS and OS between the two groups in the remaining subtypes. In the survival analysis of different clinical stages, the overall survival rates of MMBC patients in clinical stages I and II were significantly lower than those of UFBC patients (P = 0.017, P = 0.019)(The specific data analysis is not presented). Kaplan-Meier survival curves of two groups of individuals. (a) The difference in DFS between MMBC and UFBC (Log-rank test P = 0.199); (b) The difference in OS between MMBC and UFBC (Log-rank test P = 0.003). Univariate analysis of DFS and OS in MMBC patients Regarding DFS univariate analysis showed menstrual status (P = 0.021), T stage of the main lesion (P = 0.012), N stage (P < 0.001), clinical stage (P < 0.001), vascular tumor thrombus of the main lesion (P = 0.005), nerve invasion of the main lesion (P = 0.002), soft tissue infiltration of the main lesion (P = 0.019), and secondary lesion vascular tumor thrombus (P = 0.004), sub-lesion nerve invasion (P = 0.011), and postoperative adjuvant radiotherapy (P = 0.008) were significantly associated with DFS, while age, lesion number, heterogeneity, immunohistochemical expression, chemotherapy, endocrine therapy, and targeted therapy had no significant effect on DFS (P > 0.05) (Table 2) (Fig. 3a-b). Table 2Univariate analysis of DFS in patients with MMBC.CharacteristicsGroupAll(n = 262)Number of eventsP valueAge≤ 405450.847> 4020819Menstrual statusPremenopausal1428 0.021 Postmenopausal12016Surgical methodMastectomy233230.268Breast-conserving surgery291Number of lesions2212200.708≥ 3504HeterogeneityNo210220.207Yes522T staging of the main lesionT11508 0.012 T2 ~ T411216N stagingN01617 < 0.001 N1 ~ N310117Clinical stagingⅠ1094 < 0.001 Ⅱ12510Ⅲ2810Histological type of the main lesionInvasive ductal carcinoma194160.763Invasive lobular carcinoma142Other invasive carcinomas546Histological grade of the main lesionⅠ800.250Ⅱ19216Ⅲ628ER of the main lesionNegative4530.318Weakly positive82Positive20919PR of the main lesionNegative6380.573Weakly positive282Positive17114HER2 of the main lesionNegative208180.551Positive546Ki-67 of the main lesion≤ 14%6940.313>14%19320Molecular subtype of the main lesionHer2(+)2020.666luminal A573luminal B16017triple252Vascular tumor embolus of the main lesionNo21115 0.005 Yes519Neural invasion of the main lesionNo25521 0.002 Yes73Soft tissue invasion of the main lesionNo26023 0.019 Yes21Histological type of the secondary lesionInvasive ductal carcinoma193180.815Invasive lobular carcinoma132Other invasive carcinomas564Histological grade of the secondary lesionⅠ1000.386Ⅱ19417Ⅲ587T staging of the secondary lesionT1243210.215T2193ER of the secondary lesionNegative4330.440Weakly positive92Positive21019PR of the secondary lesionNegative6380.432Weakly positive273Positive17213HER2 of the secondary lesionNegative210170.229Positive527Ki-67 of the secondary lesion≤ 14%8160.606>14%18118Molecular subtype of the secondary lesionHer2(+)2020.743luminal A674luminal B15316triple222Vascular tumor embolus of the secondary lesionNo21315 0.004 Yes499Neural invasion of the secondary lesionNo25321 0.011 Yes93Soft tissue invasion of the secondary lesionNo259230.175Yes31ChemotherapyNo3820.445Yes22422RadiotherapyNo1407 0.008 Yes12217Endocrine therapyNo4940.786Yes21320Targeted therapyNo207170.288Yes557 Univariate analysis of DFS in patients with MMBC. Kaplan-Meier survival curves of independent risk factors influencing prognosis in MMBC based on clinicopathological characteristics. (a) Correlation between menopausal status and DFS (Log-rank test P = 0.021); (b) Correlation between clinical staging and DFS (Log-rank test P < 0.001); (c) Correlation between menopausal status and OS (Log-rank test P = 0.019). Regarding OS univariate analysis showed menstrual status (P = 0.019), N stage (P = 0.019), clinical stage (P < 0.001), main lesion vascular tumor thrombus (P = 0.013) and nerve invasion (P = 0.007), secondary lesion vascular tumor thrombus (P = 0.012) and nerve invasion (P = 0.018), and postoperative radiotherapy (P = 0.026) was significantly correlated with OS, while the remaining features showed no statistical significance (Table 3) (Fig. 3c). Table 3Univariate analysis of OS in patients with MMBC.CharacteristicsGroupAll(n = 262)Number of eventsP valueAge≤ 405430.803> 4020812Menstrual statusPremenopausal1424 0.019 Postmenopausal12011Surgical methodMastectomy233140.577Breast-conserving surgery291Number of lesions2212120.953≥ 3503HeterogeneityNo210140.267Yes521T staging of the main lesionT115070.366T2 ~ T41128N stagingN01615 0.019 N1 ~ N310110Clinical stagingⅠ1093 < 0.001 Ⅱ1256Ⅲ286Histological type of the main lesionInvasive ductal carcinoma194100.528Invasive lobular carcinoma142Other invasive carcinomas543Histological grade of the main lesionⅠ800.480Ⅱ19210Ⅲ625ER of the main lesionNegative4520.086Weakly positive82Positive20911PR of the main lesionNegative6350.537Weakly positive282Positive1718HER2 of the main lesionNegative208110.508Positive544Ki-67 of the main lesion≤ 14%6930.636>14%19312Molecular subtype of the main lesionHer2(+)2020.717luminal A572luminal B16010triple251Vascular tumor embolus of the main lesionNo2119 0.013 Yes516Neural invasion of the main lesionNo25513 0.007 Yes72Soft tissue invasion of the main lesionNo260150.779Yes20Histological type of the secondary lesionInvasive ductal carcinoma193110.389Invasive lobular carcinoma132Other invasive carcinomas562Histological grade of the secondary lesionⅠ1000.815Ⅱ19412Ⅲ583T staging of the secondary lesionT1243130.270T2192ER of the secondary lesionNegative4320.144Weakly positive92Positive21011PR of the secondary lesionNegative6360.283Weakly positive271Positive1728HER2 of the secondary lesionNegative210100.172Positive525Ki-67 of the secondary lesion≤ 14%8130.434>14%18112Molecular subtype of the secondary lesionHer2(+)2020.626luminal A672luminal B15310triple221Vascular tumor embolus of the secondary lesionNo2139 0.012 Yes496Neural invasion of the secondary lesionNo25313 0.018 Yes92Soft tissue invasion of the secondary lesionNo259150.680Yes30ChemotherapyNo3810.446Yes22414RadiotherapyNo1404 0.026 Yes12211Endocrine therapyNo4930.925Yes21312Targeted therapyNo207100.212Yes555 Univariate analysis of OS in patients with MMBC. Multivariate analysis of DFS and OS in MMBC patients Regarding DFS, multivariate analysis showed that menopausal status (HR = 2.52, 95%CI = 1.07–5.98, P = 0.035) and clinical stage III (HR = 8.44, 95%CI = 2.46–28.87, P < 0.001) were independent risk factors for DFS in patients with MMBC. The protective effect of radiotherapy on DFS was counteracted in the multivariate analysis (Table 4). Table 4Multivariate Cox regression survival analysis of DFS in patients with MMBC.CharacteristicsGroupP valueHR (95%CI)Menstrual statusPremenopausal1.00Postmenopausal 0.035 2.52 (1.07 ~ 5.98)Clinical stagingⅠ1.0Ⅱ0.1482.38 (0.74 ~ 7.71)Ⅲ < 0.001 8.44 (2.46 ~ 28.87) Multivariate Cox regression survival analysis of DFS in patients with MMBC. Regarding OS, multivariate analysis showed that menopause (HR = 4.60, 95%CI = 1.45–14.60, P = 0.010) was an independent risk factor for OS in patients with MMBC. The vascular tumor embolus of the main lesion (HR = 2.82, 95%CI = 0.93–8.53, P = 0.067), and radiotherapy (HR = 3.04, 95%CI = 0.90-10.31, P = 0.074) showed a potential trend, but the difference was not statistically significant (Table 5). Table 5Multivariate Cox regression analysis of OS in patients with MMBC.CharacteristicsGroupP valueHR (95%CI)Menstrual statusPremenopausal1.00Postmenopausal 0.010 4.60 (1.45 ~ 14.60)Vascular tumor embolus of the main lesionNo1.00Yes0.0672.82 (0.93 ~ 8.53)RadiotherapyNo1.00Yes0.0743.04(0.90 ~ 10.31) Multivariate Cox regression analysis of OS in patients with MMBC. Discussion For multifocal/multicentral breast cancer, previous literature has shown that compared with patients with UFBC, patients with MMBC not only have a younger age at initial diagnosis, larger tumors, more regional lymph node involvement, but also are mostly in the premenopausal stage7,24–27. This study analyzed the differences in clinical characteristics between patients with MMBC and those with UFBC and concluded that the MMBC population shows a younger onset feature (the proportion of patients aged ≤ 40 years is higher, 20.6% vs. 8.8%). Moreover, the proportion of premenopausal patients was significantly higher than that of UFBC patients (54.2%vs38.3%), suggesting that hormone sensitivity may be involved in its pathogenesis. In the multivariate analysis, this study adopted the stepwise regression method with the aim of establishing a streamlined prognostic model. Therefore, only the predictors with independent statistical significance in the multivariate analysis were listed in the report. Some variables that were significant in the univariate analysis (such as vascular tumor thrombus, nerve invasion, etc.) failed to enter the final model, indicating that their impact on prognosis may be explained or masked by other stronger factors (such as lymph node stage), or their effects may no longer be significant after multi-factor adjustment. One of the notable features of MMBC is tumor heterogeneity, which implies that the histological origin of MMBC is more complex. However, current research has not reached a clear conclusion on its formation mechanism28. In this study, all cases with mixed histological components were included in the “Other Types of invasive carcinoma” category of histological types, making the proportion of this classification as high as 20.6%. This broad classification blurs the impact of histological types on prognosis. In the future, a large number of samples need to be collected and the classification refined to explore whether the prognosis of MMBC patients is correlated with histological types. In addition, in the era of precision medicine, accurately assessing the molecular typing of different tumor foci is of great significance for formulating treatment plans10,12,13,29. Clinically, it is generally believed that biomarkers can only be evaluated in the largest single tumor lesion. However, the research results of Shuai Li et al. in June 2022 showed that 24.0% of MMBC had heterogeneity in ER, PR, HER2 and Ki-67. This was associated with greater use of adjuvant endocrine therapy (P = 0.046) and shorter DFS(P = 0.041), indicating the necessity of molecular typing assessment of different tumor foci in MMBC patients. The study also found that patients with heterogeneity among lesions had poorer DFS and OS in clinical practice compared with the homogeneous group. Although the difference was not statistically significant10. In this study, there were 210 cases (80%) without heterogeneity among MMBC lesions and 52 cases (20%) with heterogeneity. However, the impact on prognosis was not observed in the multivariate analysis and might be related to the intervention effects of other treatment methods. These findings are worthy of further exploration of the necessity of immunohistochemistry for all tumor lesions of breast cancer, which will ensure that patients with multifocal breast cancer are recommended for appropriate individualized treatment. The current T staging criteria of the American Joint Committee on Cancer (AJCC) are classified based on the diameter of the largest tumor lesion, ignoring the diameters of other secondary lesions. This may not represent the total tumor burden of MMBC patients30,31, suggesting that the existing clinical staging system has deficiencies in evaluating MMBC. The estimates of recurrence, metastasis and death risks may be underestimated, ignoring the mismatch between treatment decisions and secondary lesions27,32,33. Some previous studies have attempted to evaluate all tumor foci of MMBC using different staging methods, but the research results have not reached a consensus5,26,32,34. These contradictory conclusions highlight the difficulty of quantifying multifocal tumor burden. It is worth noting that recent studies have also pointed out that lymphovascular invasion, as an important pathological feature, can supplement the insufficiency of TNM staging in prognosis judgment, further indicating that relying solely on tumor size and lymph node status may not be sufficient to comprehensively assess the invasiveness of the disease35. Despite this, in the multivariate analysis of this study, the disease-free survival risk ratio of clinical stage III determined by existing standards was as high as 8.44, indicating that it is an extremely powerful prognostic indicator. This strongly suggests that if the information of secondary lesions can be integrated into the staging, it is expected to construct a prognostic model with stronger predictive ability. In addition, the sample size of MMBC patients in this study was relatively small, so no different methods were attempted to re-evaluate the correlation between T stage and prognosis. In the future, more precise measurement tools need to be developed to provide a reliable basis for formulating individualized treatment plans for MMBC patients. In terms of surgical treatment, through preoperative MRI precise assessment combined with intraoperative margin monitoring, some MMBC patients can achieve breast-conserving treatment. However, achieving a negative margin is technically very demanding. Therefore, accurate tumor localization and precise resection are crucial, although there is no consistent evidence that increasing the width of the negative margin will reduce the local recurrence rate. A meta-analysis published by Houssami et al. demonstrated a higher rate of local failure with positive resection margins36. Additionally, in August 2020, Ghamrini et al. employed different techniques for mammography localization in multifocal cancers to ensure a lower incidence of positive resection margins. They reported two cases (7.7%) of reoperation due to positive resection margins37. In terms of survival, in 2023, Miao Yu et al. conducted a retrospective analysis of the survival rates of breast-conserving surgery and mastectomy in patients with multifocal/multicentral breast cancer and concluded that for early-stage, well-prognostic, and treatment-sensitive patients, BCS had no survival advantage, while mastectomy had a greater survival advantage38. However, some studies have found that in appropriately selected MMBC patients, the probability of local recurrence is comparable to that reported for single-focus disease39,40. In this study, the lesion margins of all MMBC patients who underwent breast-conserving surgery were negative. Although the proportion of enrolled MMBC patients who underwent breast-conserving surgery was relatively low (11.1%), survival analysis showed no significant difference in prognosis between breast-conserving surgery and mastectomy. Future sample expansion is needed to verify its safety. Based on some previous studies7,34, the results of this study show that the OS of MMBC patients is significantly worse than that of UFBC (P = 0.003), and this difference may be caused by multiple factors: Firstly, since the median follow-up time may not be sufficient to capture the situation of late recurrence, and during the follow-up period, death caused by any reason, including non-breast cancer causes, is more likely to be detected, especially in older and postmenopausal patients. Secondly, comorbidities such as cardiovascular diseases, metabolic disorders or other malignant tumors may have an exceptionally significant impact on MMBC patients, thereby increasing non-cancer-related mortality without affecting the breast cancer-specific progression-free survival. Thirdly, the differences in treatment accessibility and tolerance may also play a role: in our cohort, MMBC patients received chemotherapy and targeted therapy less frequently, which might be due to age, comorbidities or socioeconomic factors, which could affect long-term survival. Moreover, MMBC patients may have a higher tumor burden and a higher rate of lymph node metastasis, and their responsiveness or tolerance to subsequent treatments may be inferior to that of UFBC patients, resulting in a shorter OS. This suggests that for MMBC patients, not only the risk of recurrence needs to be paid attention to, but also more active support and management should be provided in the second-line and later treatments after disease progression. Fourth, the tumor heterogeneity of MMBC, including the inconsistency of molecular subtypes among different lesions, may reduce the effectiveness of systemic treatment in the long term without leading to an increase in early detectable recurrence events. In addition, in molecular typing, the OS of luminal B type MMBC patients was significantly worse than that of UFBC (P = 0.004), while no difference was observed in other molecular typing. This might be related to the high proliferative activity of Luminal B type itself (Ki-67 > 14%) and resistance to endocrine therapy. The findings of this study have significant clinical significance. Firstly, for young, premenopausal breast cancer patients, if the imaging suggests MMBC, the possible higher invasiveness should be considered41. Before the operation, the tumor range needs to be carefully evaluated to formulate the best surgical plan. Secondly, patients diagnosed with MMBC, especially those who have been postmenopausal or have a large number of lymph node metastases, should be regarded as high-risk groups and may require closer follow-up and more aggressive adjuvant treatment strategies. Thirdly, this study highlights that MMBC has a higher tumor burden and heterogeneity risk, and the traditional AJCC T staging system may underestimate its true tumor burden. For patients suspected of having MMBC, the application of MRI can more accurately assess the number, extent of lesions and their relationship with surrounding tissues, this provides critical information for formulating the optimal surgical plan, with the aim of achieving a negative resection margin during the initial operation and reducing the risk of local recurrence. In addition, all the breast-conserving patients enrolled in this study had successful surgeries with negative margins, and there was no significant difference in prognosis compared with mastectomy. This provides data support from the Chinese population for the safe implementation of breast-conserving surgery in some MMBC patients, encouraging clinicians not to give up the breast-conserving option easily, but to comprehensively evaluate the distribution, size of the lesion and the ratio of breast volume. And through technical means (such as preoperative guidewire localization of multiple lesions), complete resection is ensured. Under the premise of ensuring oncological safety, the quality of life of patients is improved. The research also shows that the proportion of MMBC patients receiving adjuvant chemotherapy and targeted therapy is significantly lower, suggesting that clinicians need to carefully assess the treatment intensity for MMBC patients. Treatment should not be downgraded easily due to certain characteristics (such as being younger) or concerns about tolerance, especially for patients with invasive subtypes of MMBC such as HER2-positive or triple-negative. Ensuring adequate and standardized systemic treatment may be the key to improving their long-term survival. In addition, immunohistochemical detection was conducted on all lesions in this study. Although it did not show significance in prognosis analysis, it is recommended that in clinical practice and future guidelines, independent molecular typing detection should be considered for all accessible lesions of MMBC (at least the largest and second largest lesions) to avoid insufficient treatment and achieve true individualized precision medicine. It is worth noting that in the OS multivariate analysis, the main lesion vascular tumor thrombus also showed a relatively high hazard ratio compared with radiotherapy (2.82 and 3.04, respectively), although the confidence interval crossed 1 and the P value was at the critical significance level (P = 0.067 and P = 0.074). This result suggests that the aggressive biological behavior of the tumor (vascular tumor thrombus) and the higher disease burden reflected by the possible need for radiotherapy may play an important role in the prognosis of MMBC, which is worthy of further exploration in larger-sample studies. This study has several limitations. Firstly, there is a possibility of selection bias and uncontrollable confounding factors in the retrospective design. Although we adopted strict inclusion and exclusion criteria and conducted a multivariate analysis to adjust for known confounding factors, However, some unmeasured variables (such as specific details of chemotherapy regimens, details of patients’ comorbidities, socioeconomic factors, etc.) may still have an impact on prognosis. Secondly, due to the limitations of the original medical records, we failed to precisely distinguish between MFBC and MCBC, and instead combined them into MMBC for analysis, which might have masked their respective unique prognostic characteristics. Thirdly, the sample size of this study is still insufficient, especially in the MMBC group, which leads to a low number of events (recurrence or death) in some subgroups in the multivariate Cox regression analysis, resulting in extremely unstable hazard ratios calculated (manifested as extremely wide confidence intervals). Furthermore, the rate of breast-conserving surgery in this study was relatively low, which might reflect the historical tendency in clinical practice to prefer mastectomy in the case of multiple lesions to achieve negative margins and reduce the risk of local recurrence. Despite these limitations, the results of this study still provide valuable clinical insights into the clinicopathological features of MMBC and its prognostic factors. In conclusion, exploring the correlation between the clinicopathological features and prognosis of MMBC remains challenging. Future research should focus on integrating multimodal imaging and clinicopathological big data to deeply analyze the heterogeneous nature of MMBC and its precise prognosis prediction42, thereby assisting clinicians in optimizing surgical planning and systemic treatment strategies. This will thus promote the individualized and precise diagnosis and treatment of MMBC to a new level. Author contributions Conception and design: H-j W, Z N. Collection and assembly of data: J-x Z, H F, Z-w Z, Y-q G, Y L。Data analysis and manuscript writing: J-x Z, Z N, Y W, X G. Approval: All authors. Funding This work was supported by grants from the Natural Science Foundation of Liaoning Province(2023-BS-157). Data availability The data sets used and/or analyzed in this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jiaxin Zhang, Hong Fang and Ziwei Zhao contributed equally to this work. Contributor Information Zhen Ning, Email: ningzhendl@163.com. Hongjiang Wang, Email: wanghj2001@outlook.com. References Associated Data Data Availability Statement The data sets used and/or analyzed in this study are available from the corresponding author upon reasonable request.